Biospherics.net Inc. was launched in 2013 as a scientific research company. The company is focused on biological and pharmaceutical research as well as information technology. The Company’s mission is to create and grow shareholder value through innovations that benefit its clients and the human condition.
Biospherics.net develops drugs for treating orphan diseases, especially pediatric rare diseases and tropical diseases, including Prader Willi Syndrome, Ebola and Chikungunya virus infections, and ADHD in Fragile X Syndrome. Recently, studies of BSN389 (the Ebola therapeutic) have begun against the virus that causes COVID-19.